ArticleDiscover oncology2025
Identification of TMEM100's role in immune infiltration regulation and construction of an endogenous RNA network in prostate cancer through pan-cancer analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate adenocarcinoma (PRAD) is a prevalent urinary tumor with an elusive etiology. While transmembrane protein 100 (TMEM100) plays diverse roles in various cancers, its involvement in prostate cancer remains unexplored. Herein, we aim to elucidate the impact of TMEM100 on prostate cancer diagnosis and progression.
methodsUtilizing data from the TCGA database, we analyzed mRNA sequences, clinical information, and methylation data. Prognostic analysis was conducted using the GEPIA database, and a nomogram was developed using the "rms" package in R software. Drug sensitivity was assessed using the "pRRophetic" package. The correlation between TMEM100 and immune infiltration was investigated using the TIMER and TISDIB databases. Methylation levels were evaluated using Perl and R software. The competitive endogenous RNA (ceRNA) network was constructed using the starBase database. Functional assays including qRT-PCR, CCK8, EdU, and IHC assays were employed to evaluate TMEM100's role in PRAD.
resultsTMEM100 expression was significantly reduced in prostate cancer tissues compared to normal tissues, correlating with poor prognosis in PRAD. The multivariable model nomogram demonstrated enhanced prediction of PFI. Additionally, the low-expression TMEM100 group exhibited lower IC50 values for several chemotherapy drugs. TMEM100 was closely associated with various immune cell types, immunomodulators, and chemokines, exerting anti-tumor effects. Higher methylation levels of TMEM100 were observed in PRAD, with specific CpG sites showing significant correlation. TMEM100 hypermethylation correlated with immune infiltration in PCa. Furthermore, a TMEM100-related ceRNA network was constructed in PRAD, corroborating TMEM100's role in PCa through functional experiments.
conclusionTMEM100 downregulation, through modulation of immune infiltration and epigenetic mechanisms, correlates with poor prognosis and tumor cell proliferation in PRAD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.